Molecular Imaging in the Clinical Arena

Jaffer, Farouc A.; Weissleder, Ralph

doi:10.1001/jama.293.7.855

Cited by 329 publications

(219 citation statements)

References 54 publications

(75 reference statements)

Supporting

Mentioning

214

Contrasting

Unclassified

Order By: Relevance

“…The discovery of the genetic bases of neoplasia has led to new approaches to detect tumors noninvasively (6)(7)(8). Several of these approaches rely on the ex vivo detection of mutant forms of the oncogenes and tumor suppressor genes that are responsible for the initiation and progression of tumors.…”

mentioning

confidence: 99%

Detection and quantification of mutations in the plasma of patients with colorectal tumors

Diehl

Dressman

et al. 2005

Proc. Natl. Acad. Sci. U.S.A.

1,072

827

View full text Add to dashboard Cite

The early detection of cancers through analysis of circulating DNA could have a substantial impact on morbidity and mortality. To achieve this goal, it is essential to determine the number of mutant molecules present in the circulation of cancer patients and to develop methods that are sufficiently sensitive to detect these mutations. Using a modified version of a recently developed assay for this purpose, we found that patients with advanced colorectal cancers consistently contained mutant adenomatous polyposis coli (APC) DNA molecules in their plasma. The median number of APC DNA fragments in such patients was 47,800 per ml of plasma, of which 8% were mutant. Mutant APC molecules were also detected in >60% of patients with early, presumably curable colorectal cancers, at levels ranging from 0.01% to 1.7% of the total APC molecules. These results have implications for the mechanisms through which tumor DNA is released into the circulation and for diagnostic tests based on this phenomenon.colorectal cancer ͉ plasma DNA ͉ tumor suppressor gene ͉ circulating DNA ͉ diagnosis

show abstract

mentioning

confidence: 99%

Detection and quantification of mutations in the plasma of patients with colorectal tumors

Diehl

Dressman

et al. 2005

Proc. Natl. Acad. Sci. U.S.A.

1,072

827

View full text Add to dashboard Cite

show abstract

“…Most probes synthetized for molecular imaging will be limited to experimental research, since the approval process for human use involves similar hurdles as those for registering drugs [44]. Nevertheless, for target validation and assessments of drug distribution in animals, molecular imaging is going to play a relevant role in drug discovery.…”

Section: Measuring At Different Spatial Scalesmentioning

confidence: 99%

In Vivo magnetic resonance techniques and drug discovery

Beckmann¹

2006

Braz. J. Phys.

View full text Add to dashboard Cite

The long and resource intensive process of drug discovery and development is confronted with the basic challenge of providing effective and safe therapies at reasonably low costs. The better the mechanism of a disease is known, the higher the probability to find an appropriate therapy. Also, the better and earlier a disease can be diagnosed and characterized, the higher the chance to be able to interfere in this process with a chemical entity. This reasoning sets the framework for the use of imaging in drug discovery. We discuss the relevance of magnetic resonance imaging and spectroscopy to derive anatomical, functional, metabolic and target-related information in the context of pharmacological research in vivo.

show abstract

“…Individual variability in response to disease or treatment stresses the need for imaging tools which are capable of early detection and therapy monitoring. Molecular imaging is emerging as one of the technologies that will be able to fulfi l these needs (2,3) .…”

Section: Introductionmentioning

confidence: 99%